In the course of these findings, EZH2 inhibitors have been developed, representing an emerging group of new therapeutics in patients with recurrent and relapsed DLBCL, and constituting the first biomarker-directed therapy in refractory FL [14, 15, 25, 26]. This evidence concerns the gene EZH2 and diffuse large B-cell lymphoma.